All articles
Recruitment StrategyAugust 10, 2026·2 min read

Rare Disease Recruitment: When Your Catchment Is a Country

Standard recruitment playbooks assume a local population. Rare disease studies demand patient-community partnership and long-distance logistics.

By Trialflow Team

When the total diagnosed population in your metro area is eleven people, geo-targeted ads and registry filters stop being the plan. Rare disease recruitment inverts the standard model: patients are scarce, identified, and often better networked than the sites recruiting them.

The community is the channel

Rare disease patients organize. Foundations, advocacy groups, condition-specific forums, and annual patient conferences concentrate exactly the population a site needs — and they are gatekept by leaders who have seen research come and go.

Approach as a partner, not an advertiser. Advocacy groups respond to sites that show up before the study — presenting at meetings, answering questions, contributing expertise — and that share results afterward. A cold "please post our flyer" email is the mark of a site that will be gone in a year, and communities know it.

Work with foundation registries. Many advocacy organizations maintain patient registries with research-contact consent. These are the highest-density recruitment resources in existence for their conditions; earning access to them is worth months of relationship work.

Design for distance

If the eligible population is national, the site's logistics must be too:

  • Travel support, arranged not reimbursed. Booking flights and hotels for the family beats mailing forms after the fact — and the difference shows in conversion.
  • Compress visit schedules. Cluster procedures so a cross-country trip covers what the protocol allows.
  • Push everything remote-able remote. Local labs, telehealth follow-ups, and home nursing where the protocol permits turn an impossible participation burden into a manageable one.

Coordinate, don't compete, with physician referrers. For rare conditions, a handful of specialist clinics see most patients. Those specialists are colleagues in a small world; treat every interaction accordingly.

Rare disease enrollment runs on trust density, not audience size. The sites that succeed are members of the community before they're vendors to it.

Enrolling studies shouldn't be this hard

Trialflow gives research sites one platform for lead management, AI trial matching, and recruitment analytics.

Request a Demo